β3 adrenoceptor agonists show an antidepressant-like profile in preclinical rodent assays and improve mood in clinically-obese patients. These observations suggest a possible antidepressant utility for β3 adrenoceptor agonists. The present study examined the effects of acute and chronic administration of the β3 adrenoceptor agonist CL 316243 on two physiological indicators of antidepressant activity in the rat: hypothalamic 5-HT synthesis and suppression of REM sleep. 5-HT synthesis was estimated by the accumulation of 5-hydroxytryptophan (5-HTP) after treatment with the L-aromatic acid decarboxylase inhibitor NSD 1015. Sleep-wake patterns were monitored using electroencephalogram and electromyogram signals collected by radiotelemetry. Rats were administered CL 316243 acutely or once daily for 11 days. Acute administration of CL 316243 significantly increased hypothalamic 5-HT synthesis, as indicated by increased levels of 5-HTP, and reduced the amount of REM sleep. However, chronic administration produced no changes in 5-HTP or REM compared with vehicle treatment. The present observations suggest that acute administration of CL 316243 causes antidepressant-like effects on REM sleep, possibly mediated by increased central 5-HT synthesis. However, these effects are not maintained with repeated dosing.
Arch J R S, Ainsworth A.T., Cawthornw M.A., Piercy V., Sennitt M.V., Thody V.E., Wilson C., Wilson S. (1984) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature309: 163—165
2.
Barton C.L., Hutson P.H. (1999) Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors . Synapse31: 13—19
3.
Bloom J.D., Dutia M.D., Johnson B.D., Wissner A., Burns M.G., Largis E.E., Dolan J.A., Claus T.H. (1992) Disodium (R,R)-5-[2-[[-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243). A potent β-adrenergic agonist virtually specific for β3 receptors. A promising antidiabetic and antiobesity agent. J Med Chem35: 3081—3084
4.
Brambilla A., Baschirotto A., Grippa N., Borsini F. (1999) Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain. Eur Neuropsychopharmacol10: 63—67
5.
Carlsson A., Davis J.N., Kehr W., Linqvist M., Atack C.V. (1972) Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn SchmeidebergsArch Pharmacol275: 153—168
6.
Ceglia I., Acconcia S., Fracasso C., Colovic M., Caccia S., Invernizzi R.W. (2004) Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol142: 469—478
7.
Connacher A.A., Lakie M., Powers N., Elton R.A., Walsh E.G., Jung R.T. (1990) Tremor and the anti-obesity drug BRL 26830A. Br J Clin Pharmacol30: 613—615
8.
Dicioccio A.T. (1997) The pharmacokinetics and biodistribution of a novel beta 3 agonist in the rat utilizing microdialysis (CL 316243, BTA 243). St John's University, Jamaica, NY, USA, pp. 149
9.
Edwards D.J., Sorisio D.A. (1988) Effects of imipramine on tyrosine and tryptophan are mediated by β-adrenoceptor stimulation. Life Sci42: 853—862
10.
Edwards D.J., Sorisio D.A., Knopf S. (1989) Effects of the β2-adrenoceptor agonist clenbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochem Pharmacol38: 2957—2965
11.
Elhwuegi A.S. (2004) Central monoamines and their role in major depression . Prog Neuropsychopharmacol Biol Psychiatry28: 435—451
12.
Eriksson T., Carlsson A. (1988) β-adrenergic control of brain uptake of large neutral amino acids. Life Sci42: 1583—1589
13.
Evans B.A., Papaioannou M., Bonazzi V.R., Summers R.J. (1996) Expression of beta 3-adrenoceptor mRNA in rat tissues . Br J Pharmacol117: 210—216
14.
Hutson P.H., Bristow L.J., Thorn L., Tricklebank M.D. (1991) R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine . Br J Pharmacol103: 2037—2044
15.
Ivarsson M., Paterson L.M., Hutson P.H. (2005) Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats. Eur J Pharmacol522: 63—71
16.
Kantor S., Jakus R., Bodizs R., Halasz P., Bagdy G. (2002) Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity, and sleep: changes at the light-dark phase shift. Brain Res943: 105—111
17.
Kim S.W., Park S.Y., Hwang O. (2002) Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. MolecularPharmacol61: 778—785
18.
Larsen T.M., Toubro S., van Baak M.A., Gottesdiener K.M., Larson P., Saris W H M, Astrup A. (2002) Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men . Am J Clin Nutr76: 780—788
19.
Lecrubier Y., Puech A.J., Jouvent R., Simon P., Widlocher D. (1980) A beta adrenergic stimulant (salbutamol) versus clomipramine in depression: a controlled study. Br J Psychiatry136: 354—358
20.
Lenard N.R., Gettys T.W., Dunn A.J. (2003) Activation of β2- and β3-adrenergic receptors increases brain tryptophan. J PET205: 653—659
21.
Lyrenas E., Abrahamsson H., Dotevall G. (1985) Rectosigmoid motility response to beta-adrenoceptor stimulation in patients with irritable bowel syndrome. Scand J Gastroenterol20: 1163—1168
22.
MacLachlan M., Connacher A.A., Jung R.T. (1991) Psychological aspects of dietary weight loss and medication with the atypical beta agonist BRL 26830A in obese subjects. Int J Obesity15: 27—35
23.
Moret C., Briley M. (1992) Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacol31: 679—684
24.
Sharpley A.L., Cowen P.J. (1995) Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry37: 85—98
25.
Simiand J., Keane P.E., Guitard J., Langlois X., Gonalons N., Martin P., Bianchetti A., Le Fur G., Soubrie P. (1992) Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical β-adrenoceptors. Eur J Pharmacol219: 193—201
26.
Stenfors C., Ross S.B. (2002) Evidence for involvement of 5-hydroxytryptamine1B autoreceptors in the enhancement of serotonin turnover in the mouse brain following repeated treatment with fluoxetine. Life Sci71: 2867—2880
27.
Stenfors C., Yu H., Ross S.B. (2001) Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram. Naunyn-Schmiedeberg's Arch Pharmacol363: 222—232
28.
Summers R.J., Papaioannou M., Harris S., Evans B.A. (1995) Expression of beta 3-adrenoceptor mRNA in rat brain . Br J Pharmacol116: 2547—2548
29.
van Baak M.A., Hul G B J, Toubro S., Astrup A., Gottesdiener K.M., DeSmet M., Saris W.H. (2002) Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther71: 272—279
30.
Waal H.J. (1967) Propranolol-induced depression. Br Med Journal2: 50
31.
Widlocher D., Lecrubier Y., Jouvent R., Puech A.J., Simon P. (1977) Antidepressant effect of salbutamol. Lancet2: 767—768
32.
Wilson S., Argyropoulus S. (2005) Antidepressants and sleep: a qualitative review of the literature. Drugs65: 927—947
33.
Winokur A., Gary K.A., Rodner S., Rae-Red C., Fernando A.T., Szuba M.P. (2001) Depression, sleep physiology, and antidepressant drugs. Depress Anxiety14: 19—28
